[Type here] appears to be mediated through the complement cascade of the immune system. Normally, the complement cascade detects and destroys blood born bacteria. It can be activated via an antibodydependent pathway (the "classical pathway"), an antibody-independent pathway (the "alternate pathway"), or on binding to specific carbohydrates on the surface of microorganisms (the "lectin" pathway). Complement was first implicated in the pathogenesis of AMD in 2005, when a common variant in complement factor H (CFH) gene was noted to be strongly associated with AMD, with individuals homozygous for the risk allele possessing a 7.4 fold increased risk [42, 43] ; several other genetic variants in complement genes have since been associated with AMD [44] [45] [46] . CFH is a natural inhibitor of factor C3 activation, which is central to the three pathways. Complement is involved in drusen formation , and genetic variations in CFH can lead to less effective modulation of complement pathway activity, leading to greater precipitation of complement protein observed in drusen [47] . The final common pathway of complement activation, factor C5, is cleaved to form key terminal fragments (C5a and C5b-9) regardless of which pathway (classical, alternate or lectin) induced their generation. The C5a fragment, observed in drusen of AMD patients, is an important inflammatory activator, recruiting inflammatory cells and inducing vascular endothelial growth factor (VEGF) expression from RPE cells [48] . C5b is involved in the formation of the membrane attack complex (MAC: C5b-9), which causes cell death through disruption of the cell membrane. In humans, deposition of MAC in Bruch's membrane and choriocapillaris increases significantly with aging and with AMD [49] . When choroidal endothelial cells are exposed to MAC, cell lysis occurs and the surviving cells express VEGF and matrix metalloproteinases (MMP); thus, MAC deposition in the choriocapillaris may play a role in atrophic and neovascular AMD, respectively [50] . Consequently, both C5a and MAC may promote CNV, and this is supported by experimental models of CNV, in which inhibition of C5a and MAC formation prevents the development of CNV [51, 52] .
AMD pathogenesis is a chronic, complex process that affects the RPE-BM-CC complex and stem cellbased therapies will need to overcome key structural and functional changes. Additionally, if placed subretinally, any transplant will be exposed to a toxic environment, potentially affecting the survival and physiology of the transplanted cells.
3.
Induced pluripotent stem cells Human embryonic stem cells (hESCs) were first cultured in 1998 and have the potential to differentiate into all cell types [53] . They are a promising source for stem-cell based therapy but raise potential ethical considerations due to their harvesting during embryogenesis when there is potential for full development. In 2006, Takahashi and Yamanaka discovered a method of inducing a pluripotent state from terminally differentiated mouse fibroblasts, potentially addressing this issue. The introduction of four transcription factors, Oct3/4, Sox2, c-Myc and Klf4 to adult murine fibroblasts under embryonic cell culture conditions, resulted in an induced pluripotent stem cell (iPSC) state as confirmed by the ability to differentiate into all three germ layers upon transplantation into adult mice and mouse embryos [54] . One year later, two separate groups were able to create iPSCs from adult human cells, another major scientific milestone [55, 56] .
Numerous advances in the efficiency and safety of iPSC generation has occurred over the last decade. Various groups have developed methods for improving the efficiency of pluripotency induction through the use of factors such as valproic acid [57] , SV40 large T antigen [58] , and microRNA [59] . The development of iPSCs has also become safer. The original use of Myc transcription factor in the formation of iPSCs created concern that constitutively active Myc, an [Type here] oncogene, could result in tumor formation. This problem was solved in 2008 by Nakagawa et al. when they demonstrated a method of iPSCs production in mouse and human fibroblasts without the use of Myc [60] . Similarly, the safety of using retroviral vectors for creating iPSCs, and concern about retroviral integration into the DNA with unpredictable sequelae such as creating a tumorigenic state, was overcome through numerous methods including the use of non-integrating episomal vectors [61] , adenoviruses [62] , the Sendai virus [63] , piggyback transposition [64] , minicircles [65] , mRNA transfection [66, 67] , microRNAs [68] , transfection of a single multiprotein expression vectors [69] , chemicals [70] and reprogramming proteins [71] , among other techniques. The landscape of methods to effectively and efficiently induce a pluripotent state is expanding rapidly and a thorough discussion is beyond the scope of this review.
These advances over the last decade helped pave the way for the translation of iPSC-based animal and human studies. In addition to cell therapy, iPSCs have other applications, including disease modeling and drug discovery.
4.
Retinal pigment epithelium transplantation RPE replacement is of interest in AMD therapeutics research given its numerous key roles in retinal support and function, as well as its pathophysiologic roles in AMD. This section reviews RPE physiology, the history of RPE transplantation, preclinical studies, and the most recently published human studies.
4.1.
Retinal pigment epithelium physiology The RPE, a monolayer of hexagonal cells, plays numerous roles in retinal homeostasis. It is a polar layer with the apical portion facing the outer segments of the photoreceptors and the basal surface facing BM. The polarity of RPE cells aids in the transport of ions, water and metabolic products from the subretinal space to the CC [72] . It also helps in the delivery of glucose and fatty acids to the outer retina [72] . Voltage-dependent ion conductance at the apical membrane creates the appropriate ion composition in the subretinal space necessary for photoreceptor excitability [72] . Tight junctions help maintain polarity in addition to forming the outer blood-retinal barrier [73] . RPE cells apically project microvilli that facilitate retinal adhesion and processing of shed outer photoreceptor segments. These shed photoreceptor outer segments are processed by the RPE through phagocytosis and subsequently recycled to the photoreceptors or eliminated to the CC [74] . Multiple steps in the retinoid cycle are performed by the RPE cells and provide photoreceptors with 11-cis-retinal [75] . Melanin is abundantly found in RPE cells and functions by preventing light reflection and as a free radical scavenger [72] .
The RPE physiologically secretes numerous growth factors. Pigment epithelium-derived factor (PEDF) has anti-angiogenic and neurotrophic properties and is principally secreted apically by the RPE [72] . VEGF, at low levels, is secreted on the basal surface of the RPE and prevents endothelial cell apoptosis of the CC [72] . Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-3) are secreted to stabilize the endothelium, Bruch's membrane and the CC extracellular matrix [72] . Fibroblast growth factor and ciliary neurotrophic factors are secreted in response to RPE damage and have neuroprotective roles. Contributions to immune privilege and inflammation modulation is performed through the secretion of interleukins and cytokines and through the presentation of cell membrane proteins [72, 76] . Consequently, the RPE plays multiple roles in the physiology of the CC and retina through the secretion of growth factors, while also facilitating ocular immune privilege through the secretion of interleukins and cytokines [72, 77] .
[Type here] These paracrine functions of the RPE are critical for the health of the neurosensory retina. This discussion is pertinent because most stem cell based therapies in AMD strive to replace or supplement diseased RPE cells. While critical functions dependent on proper orientation and structure may be challenging to replicate with stem-cell based therapy, the paracrine functions could potentially be more easily supplanted.
4.2.
History of adjuvant retinal pigment epithelium transplantation in choroidal neovascular membrane resection
This section provides a brief discussion on the history of RPE transplants and the relevance to stem-cell based transplantation. Subfoveal neovascular membrane resection was one of numerous investigational therapies for nAMD in the 1990s [78, 79] . A major limitation of this procedure was the associated extraction of RPE and the subsequent development of GA with a poor visual prognosis [80] [81] [82] . To limit this atrophy, investigators attempted various methods of adjuvant RPE transplantation following CNV resection, including homologous fetal RPE transplantation [83] , homologous adult RPE transplantation [84, 85] , macular translocation [86] , autologous RPE transplantation [84, 87, 88] , choroidal-RPE transplantation [89, 90] , and Bruch's membrane-RPE transplantation [91] . With the advent of anti-VEGF therapy, the investigative fervor of RPE transplantation subsided, but numerous lessons can be gleaned from those studies.
Intraoperatively, manipulation of RPE grafts makes transplantation technically difficult. Maaijwee et al. published a series of 84 RPE and choroidal translocation procedures, in which 56 were associated with an inadequate positioning or incomplete flattening of the graft [92] . The graft was often partly folded or wrinkled, and 12 cases required extraction and reinsertion [92] . Joussen et al. noted that of 45 eyes receiving an autologous translocation of peripheral choroid and RPE, two patients intraoperatively and one patient postoperatively were observed to have an upside-down insertion of the graft [89] . These technical difficulties will similarly be encountered in stem-cell based therapies utilizing subretinal RPE sheets that require precise orientation, but not in stem cellbased therapies utilizing intravitreal or subretinal cellular suspensions.
Immediately post-operatively, a high rate of subretinal hemorrhage occurred in several published series. MacLaren et al. noted that 4 of 12 patients who underwent an autologous RPE and choroidal transplantation experienced a subretinal hemorrhage within 1 week of surgery [93] . Similarly, Joussen et al. observed that of 45 eyes treated with autologous choroidal and RPE transplantation, 18 experienced a massive subretinal hemorrhage postoperatively [89] . Stem-cell based therapies that create iatrogenic subretinal spaces (i.e. retinal detachment "blebs" via vitrectomy) and inject transplants through retinotomies may pose similar risks. However, a likely contributing factor to subretinal hemorrhage was the CNV resection performed prior to transplantation, which all ongoing stem cell-based studies currently avoid.
A major limitation in early RPE transplantation studies was the rejection of transplants. In a study of non-immunosuppressed allogenic fetal subretinal RPE transplants, the majority of eyes with atrophic AMD rejected the transplant and all patients with nAMD rejected the transplant [85] . Despite the relative immune privilege of the subretinal space, the immunogenicity of fetal RPE cells resulted in an unacceptable rate of rejection. The higher rejection rate for nAMD patients was thought by authors to be due new blood vessels disrupting the blood-retinal barrier. Tezel et al., seeking to overcome this immunological hurdle, investigated 12 patient receiving allogenic, adult RPE transplants and added triple immunosuppression with corticosteroids, cyclosporine and azathioprine postoperatively [94] . None of the 12 transplants experienced rejection [94] , suggesting [Type here] the need for immunosuppression in these allogenic transplants. In contrast, autologous transplants with low immunogenicity, were found to have low rates of rejection [88] . Stem cell-based therapy will need to account for the immune response to transplanted tissue, particularly if allogenic tissue is utilized.
Several case series have noted a high rate of proliferative vitreoretinopathy (PVR) following RPE transplant. For example, Joussen et al. observed that 17 of 45 eyes that underwent an autologous choroidal and RPE transplantation experienced PVR [89] . Several other case series involving autologous choroidal and RPE transplantation and macular translocation surgeries have noted high rates of PVR [90, [95] [96] [97] . PVR is likely fostered by the extensive manipulation of the retina, RPE and choroid during harvesting and may also be related to extensive manipulation of the graft during insertion through the macular retinotomy. In comparison, allograft RPE transplant studies suggest lower rates of PVR [98] , likely due to smaller retinotomies and without the need to harvest tissue from the surgical eye. We suspect that stem-cell based therapies will have similar PVR rates as the allograft studies because of less manipulation of RPE and choroid and smaller retinotomies.
4.3.
Preclinical stem-cell based retinal pigment epithelium studies Studies investigating adjuvant RPE transplants during CNV resection performed during the 1990s and early 2000s demonstrated the feasibility of subretinal transplantation, as well as the associated challenges. This section will review preclinical studies of stem cell-based RPE therapy, which demonstrated proof of mechanism prior to human studies.
The manufacturing of stem cell-based RPE transplants requires RPE cells to be created from progenitor cells, a complex process that has undergone significant evolution over the last two decades. One of the earliest and simplest methods of RPE differentiation was to allow pluripotent stem cells to undergo "spontaneous" differentiation [99] . While producing a highly pure RPE yield, the spontaneous method was lengthy and inefficient, and supplementation with various factors has improved efficiency [100, 101] . Early on, RPE differentiation utilized co-culture with mouse cells [102] , which raised reasonable ethical and clinical concerns if this resulting RPE were to be implanted into human eyes. This hurdle was overcome in 2012 by using human fibroblast feeder cells [103] as opposed to non-human feeder cells, and later by methods obviating the need for feeder cells [104] . Differentiation of desired cells is a time-consuming process, and from 2013-2016, numerous investigators have published successively more efficient methods of RPE differentiation [105] [106] [107] [108] [109] [110] [111] .
Improved efficiency and effectiveness in the production of stem cell-derived RPE cells led to numerous animal studies. Stem cell-based RPE grafts have been successfully transplanted subretinally in rats [101, [112] [113] [114] [115] , mice [116] , rabbits [117] and pigs [118] . The successful surgical implantation [112] [113] [114] [116] [117] [118] , survival [112] [113] [114] [116] [117] [118] , and in several publications the integration [117] and functional rescue of retinal function in AMD animal models [112, 113, 116, 117] paved the way for human trials.
Stem cell-derived RPE cells are mostly considered "RPE cells" based on morphology, immunostaining, electron microscopic analysis and a few functional studies. Kokkinaki et al., demonstrated that iPSC-derived RPE cells exhibit ion transport, membrane potential, polarized VEGF secretion and gene expression that is similar to native RPE [119] . Others have noted that iPSCderived RPE cells have similar mRNA expression, protein expression and rod outer segment phagocytosis when compared to fetal human RPE cells [106] . In contrast, Sugino et [121] . It remains to be seen if stem cell-based RPE cells can replicate the myriad of functions, including immunomodulatory effects, of native RPE cells in the human eye.
4.4.
Human studies of human embryonic stem cell-derived retinal pigment epithelium transplantation
The first human studies of stem cell-based RPE transplants in AMD were published in 2012 [122] . Schwartz et al. performed two prospective clinical trials assessing the safety and tolerability of subretinal transplantation of hESC-derived RPE cells in patients with Stargardt macular dystrophy and dry AMD [123] . Nine subjects with atrophic AMD and nine with Stargardt macular dystrophy were included and all had VA measuring from 20/200 to hand motion [123] . Patients underwent pars plana vitrectomy, followed by injection of 150 microliters of RPE cellular suspension into the subretinal space at preselected sites of transition between diseased and healthy retina [123] . Patients received either 50,000 cells, 100,000 cells or 150,000 cells and were immunosuppressed with tacrolimus and mycophenolate mofetil from 1 week before surgery until 12 weeks following surgery [123] .
Following surgery, 72% of patients had increased subretinal pigmentation at the location of transplantation, suggesting presence of the injected cells [123] . OCT imaging of this hyperpigmented region revealed findings consistent with a layer of cells lining Bruch's membrane [123] . At 6 months, the VA in AMD patients improved by 15 letters in four eyes, 11-14 letters in two eyes and remained stable in three eyes [123] . No significant changes were seen in visual field, static perimetry, electroretinography, or reading speed [123] . No signs of acute rejection were noted, such as prominent lymphocyte infiltration, acute or chronic moderate grade non-infectious uveitis, hyperacute rejection, cystoid macular edema, encapsulation of the transplanted cells, or whitening of the transplanted area [123] . No eyes developed abnormal growth suggestive of a teratoma, a tumor comprised of 2 or more germ layers which could originate from stem cells; and no eyes developed PVR or a retinal detachment, although four patients developed a cataract and one developed endophthalmitis [123] . At four years, no teratoma formation or abnormal differentiation of cells occurred [124] .
These results suggest the tolerability of subretinal stem cell-derived RPE therapy. Adverse events were acceptable and, importantly, there was no evidence of tumor formation or rejection. A follow-up study is currently underway that will include patients with better baseline VA, which should theoretically yield better outcomes given lower amounts of preexisting RPE-BM-CC complex damage.
In 2015, Song et al. published preliminary results of subretinal hESC-derived RPE transplantation in two patients with advanced atrophic AMD and two patients with Stargardt disease [125] . In two patients, surgical complications included difficulty creating a retinotomy site and a retinal bleb encroaching the fovea, both of which required a secondary retinotomy site [125] . In one patient, a small subretinal hemorrhage was noted postoperatively that resolved by 13 weeks [125] . Immunosuppression was stopped in one patient because of kidney damage and myelosuppression [125] . No patients developed a teratoma or immune rejection [125] . This study demonstrated the technical difficulties of performing subretinal surgery as well as the systemic risks [Type here] of immunosuppression. Similar to Schwartz et al., importantly, no rejection or teratoma formation was noted.
4.5.
Human studies of pluripotent stem cell-based retinal pigment epithelium transplantation The use of iPSC-derived RPE transplants in human trials has lagged behind the use of ESCs. The first human trial using iPSCs-derived RPE subretinal transplants was initiated by RIKEN, a research institute in Kobe, Japan in September 2014 [126] . A 70-year-old Japanese woman became the first person in the world to receive an iPSC-derived therapy [127] . Of note, she did not receive immunosuppression [127] , in comparison to the patients in ESC-derived RPE transplantation studies [123, 125] . Additionally, the patient demonstrated no adverse effects at one year, as the transplanted sheets remained intact and her vision decline had stabilized [128, 129] .
This study proved short-lived when it was suspended the subsequent year [126] . The reasons for the suspension were multifactorial and included regulatory changes in Japan, but of particular concern was the development of mutations in the second patient's iPSCs that were not detectable in the patient's original fibroblasts [126] . The genomic instability of iPSCs has been documented by other investigators [130] and the potential tumorigenicity of these cells needs to be considered in human trials. Of note, and emphasized by the investigators of the RIKEN study, mutations are not necessarily tumorigenic [127] .
In 2016, RIKEN planned to resume the study, with a significant modification. Instead of autologous cells, they are investigating HLA-matched allogenic iPSC-derived RPE cells [126] . These cells will not only be verified for genomic stability but the process of cell production will be expedited [126] . The use of autologous cells are estimated to require three months to develop and cost approximately $1,000,000 from harvesting to intraocular implantation [127] . Thus, the use of HLA-matched allogenic stem cell derived transplants are more likely to succeed financially and have the potential to be safer. A downside of using allogenic cells is the increased risk of rejection and the likely need for immunosuppression.
Another study using iPSC-derived RPE cells is currently underway at Moorfields Eye Hospital in England (Table 1 ) and other groups in the United States are working on garnering FDA approval for a US-based study [127] .
5.
Retinal progenitor cell transplantation An alternative to subretinal RPE transplantation is the subretinal transplantation of retinal progenitor cells. In 2002, Zhao et al. published a method of differentiating ESCs into retinal neurons [131, 132] . As in stem cell-based RPE research, improved methods of photoreceptor differentiation occurred over the ensuing decade [133, 134] . Additionally, various groups described methods of differentiating iPSCs into photoreceptors [100, 135, 136] , allowing for potentially fewer ethical and immunologic concerns.
Numerous preclinical studies have demonstrated the ability of neural precursor cells to integrate into the retina of animal models. Precursor cells have been derived from a variety of animal sources including adult rat brain [137, 138] , rat retina [139] , mouse embryo [140] [141] [142] [143] , mouse brain [144] , mouse spinal cord [145] , mouse retina [146] , adult mouse induced iPSCs [147] , human brain [148, 149] and human embryos [150] . These various cell sources have been injected into the vitreous cavities and subretinal spaces of numerous rat and mouse retinal degeneration models for AMD [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [149, [154] [155] [156] [157] [158] . In large animals, investigators have published the subretinal hESC-based photoreceptor transplantation in healthy squirrel monkeys, and found the transplants were able to survive 3 months and demonstrated in vivo imaging evidence of axonal projections extending into the host retina, optic nerve and retrolaminar optic nerve [159] .
Subretinal transplantation of photoreceptors is traditionally thought to result in a degree of migration and integration of the transplant within the host retina. Recently, however, research into preclinical models of photoreceptor transplantation have elucidated a novel mechanism of hosttransplant cellular interaction. Various authors have demonstrated that transplanted photoreceptors transfer proteins and/or RNA with the host tissue, without fusion of nuclei and with significantly less integration of transplanted photoreceptors than previously thought [160] [161] [162] . This novel finding has brought into question the prior understanding and conclusions of photoreceptor transplantation in animal models and the mechanism of how these transplants improve vision, in particular if there is a significant degree of integration of transplanted cells. Additionally, this discovery reveals a possible therapeutic mechanism, whereby transplanted cells transfer needed proteins and genes rather than direct tissue replacement.
In 2006, MacLaren et al., published a landmark study identifying the ideal ontogenetic stage of donor cells for successful rod photoreceptor transplantation [163] . They harvested retinal progenitor cells from normal mice and subretinally transplanted them into adult mice, neonatal mice and in three disease models [163] . They varied the age of maturation of transplanted cells and noted that progenitor cells that were aged outside the ideal ontogenetic stage did not integrate into the retina [163] . These findings highlight a catch-22 situation, where if the transplant is not terminally differentiated, then the eye has increased risk of teratoma formation; in contrast, if the transplant is terminally differentiated, then it is unlikely to properly integrate into the host retina.
Regarding safety, the intraocular transplantation of non-terminally differentiated pluripotent stem cell-based photoreceptor progenitors increases the risk of teratoma formation in several animal models [146, 155] . This observation is not surprising because of the unlimited replicative potential of pluripotent stem cells and their ability to differentiate into all cell types. This is in contrast to the transplantation of terminally-differentiated RPE cells, which through differentiation, lose the ability for further differentiation or replication. Surprisingly, even neurally-selected mouse ESCs can induce tumor formation after subretinal transplantation [140] . In this study, tumors developed 2 months following surgery even though 2 weeks after engraftment there was no hint of pathology [140] . The authors speculated that despite attempting for a pure selection of neural precursor cells, a few of the less differentiated cells were likely injected into animal eyes as well, resulting in the teratoma formation [140] . If non-terminally-differentiated stem-cell based therapies are to be used in humans, the possibility of less-differentiated cells contaminating the treatment sample must be considered.
The major limitation of these animal studies is the difficulty in simulating complex human pathologies such as AMD. Animal models of human ocular pathology usually have one pathologic process resulting in visual impairment. In contrast, AMD results in damage the CC, BM and RPE as well as local immunological changes, which is difficult to replicate in an animal model. Additionally, numerous studies investigated transplantation into young animal eyes [137, 139, 141, 148, 149] , which have a different microenvironment than aged eyes. Thus, the translatability of retinal progenitor cell [Type here] transplantation in animal models to human studies has significant limitations and there have been no human studies to date.
Challenges to effective transplantation 6.1 Surgical complications
Subretinal surgery is technically difficult and exposes patients to potential risks. Song et al., while performing subretinal transplants of ESC-derived RPE cells, had difficulty in creating a retinotomy site in two of four patients, requiring the creation of a secondary retinotomy site at a different location [125] . Each retinotomy site theoretically increases the risk of complications, including scotoma, hemorrhage, retinal detachment and PVR. In one patient, the retinotomy bleb encroached the fovea, requiring another retinotomy site [125] . In contrast, Schwartz et al., did not publish similar difficulties in 18 patients [123] . The methods of each investigator were similar, with both performing a pars plana vitrectomy, inducing of posterior vitreous detachment and injecting 150 microliters of suspended cells into the subretinal space using a 38-G cannula. However, it is likely that these authors had small differences in technique or surgical instruments to account for these differences. . Regardless, surgical challenges will undoubtedly be encountered with subretinal transplantations and these risks need to be weighed against the potential benefits.
Theoretically, fewer surgical complications should be encountered with bone marrow stem cell (BMSC)-derived therapy, an alternative stem cell source. BMSC-based treatments have largely been investigated as intravitreal therapies because the transplant is injected for a supportive paracrine effect, as opposed to a cell replacement role. However, postoperatively, patients may be at increased risk of proliferation of cells within the vitreous, as was noted in several animal models [164, 165] as well as in humans [166] , and particularly with mesenchymal stem cells.
Several case reports of adverse events following BMSC-based therapy have been published. Following intravitreal injection of CD34-positive stem cells, a 71-year-old female patient developed a visually significant epiretinal membrane within four months [167] . Another patient, a 60-year-old man with Stargardt disease, developed a retinal detachment 2 months following subretinal injection of autologous bone marrow-derived mesenchymal stem cells [168] . Most recently, Kuriyan et al., published a tragic case series of three patients who experienced retinal detachment and profound loss of vision following adipose tissue-derived mesenchymal stem cell intravitreal transplants at one center in Florida [166] . Consequently, despite the more invasive nature of the subretinal approach with iPSC therapy, it may pose lower overall risk than the intravitreal approach used with BMSCderived stem cells, which has led to significant proliferation and fibrosis within the vitreous cavity, followed by retinal detachment in a subset of patients.
Transplant immunology
The eye is relatively immunologically privileged, making it an intriguing option in the investigation of stem cell-based therapies [169] [170] [171] [172] . The mechanism for this immune privilege is complex and incompletely understood, but the RPE monolayer likely plays a critical role and is known to express and secrete transforming growth factor-beta, somatostatin, thrombospondin, PEDF and CD86, all of which either directly or indirectly modulate the immune response [173] . On a cellular level, RPE cells can induce T cell apoptosis and modulate macrophage activation by PEDF production [174, 175] .
[Type here] Ocular pathology can alter the immunological balance, as increased immunogenicity was observed in RPE transplant studies during the 1990s. Patients with nAMD had a significantly higher rate of RPE transplant rejection than those with atrophic AMD, possibly due to a CNV-induced break in the blood-retinal barrier [85] . In addition to a break in the blood-retinal barrier, patients with atrophic AMD had a high rate of rejection, albeit lower than in nAMD, suggesting a separate mechanism for ocular immunological impairment [85] . Immune suppression with corticosteroids, cyclosporine and azathioprine eliminated the immune rejection of adult RPE allografts [94] , and this method will likely be necessary in humans who receive allograft transplants.
Induced PSC-derived cells have demonstrated reduced immunogenicity [176, 177] , one of their advantages over ESC-based therapy. Furthermore, the use of autologous iPSCs is hypothesized to reduce the risk of immune rejection due to self-identification of implanted cells. The disadvantage of autologous induction of pluripotency followed by the differentiation of cells into acceptable transplants is its time-consuming and expensive nature. An alternative role for iPSCs is allogenic transplantation using HLA-matched iPSCs, similar to HLA-matched organ transplantation. Preclinical studies have supported this idea by demonstrating that iPSC-derived RPE cells lack a T cell response [178] and a non-immunosuppressed animal model utilizing MHC-matched subretinal iPSC-derived RPE transplants showed no evidence of rejection [179] . In contrast, an animal model using MHCmismatched transplants resulted in an immune attack around the graft and nearby retinal tissue [179] . In preparation for human studies, generation of iPSCs from donors who are HLA-matched with ~20% of the Japanese population has been developed [180] .
Systemic immunosuppression
Immunosuppression improves the survival of transplanted tissues but carries a significant risk. Schwartz et al. utilized low-dose tacrolimus (target blood levels of 3-7 ng/mL) and mycophenolate mofetil (MMF, ranging 0.5 g -2 g orally/day) one week prior to transplantation [123] . At six weeks, tacrolimus was discontinued and MMF was continued for an additional six weeks [123] . Several patients needed to discontinue or modify therapy due to adverse events [123] . One patient developed severe shortness of breath, moderate fatigue, moderate diarrhea and severe stomach aches, and consequently MMF was discontinued [123] . A second patient developed a UTI, resulting in the discontinuation of both medications [123] . A third patient developed endophthalmitis and immunosuppression was stopped [123] .
Song et al. similarly noted significant adverse events from systemic immunosuppression [125] . Their immunosuppressive protocol was comparable to Schwartz et al., with MMF and tacrolimus started one week prior to surgery and continued for 6 weeks postoperatively [125] . Subsequently, tacrolimus was discontinued and MMF was continued an additional 7 weeks [125] . In one patient, immunosuppression was stopped at 4 weeks postoperatively due to acute kidney injury, elevated potassium levels, bone marrow suppression and diarrhea [125] . Another patient developed pneumonia, which was treated successfully with oral antibiotics, and immunosuppression was not stopped [125] . A third patient developed herpetic vesicles on the right arm, which was possibly related to MMF immunosuppression, but immunosuppression was not stopped [125] .
These studies demonstrate that immunosuppressive medications are not without risks. The use of autologous or allogenic, HLA-matched iPSC-derived cell therapy may reduce the immune response to transplanted cells and minimize the need for potent and long-term immunosuppression. The ideal immunosuppressive medications, duration and dose remains to be determined.
[Type here]
Aging Bruch's Membrane
AMD pathogenesis results in significant changes to the retina, RPE, BM and choroid, which may limit successful subretinal RPE transplantation. Given the close anatomic and functional interactions between transplanted RPE and BM, the changes to BM are of prime importance. In vitro studies have demonstrated that aged BM alters the gene expression profile of human RPE [181] , reduces the likelihood of attachment to BM [182] and increases RPE apoptosis [183, 184] .
Various attempts have been attempted to overcome these limitations. Extensive research has been conducted to develop an effective film to support stem cell-based RPE cell growth and transplantation [185] [186] [187] [188] [189] [190] [191] [192] [193] . The goals of this film are to create an artificial attachment for stem-cell based RPE cells that would negate the need for attachment to diseased BM, as well as providing structural and physiological support. The major limitation of the film is its potential adverse effect on subretinal physiology and, for films that biodegrade, the ability of RPE cells to attach to remaining BM following dissolution of the film. The use of films has transitioned to clinical research, as can be seen in Table 1 , with two groups using a film on which RPE cells are transplanted.
Other methods to improve RPE cellular adherence to aged BM include altering integrin expression on RPE cells [194, 195] , modifying the extracellular matrix of RPE cells prior to transplantation [196] , and modifying native BM of treated eyes prior to transplantation [197] . While demonstrating preclinical effectiveness, these methods have not yet translated to human studies. Table 1 includes a list of ongoing or recently completed studies investigating various types of stem cellderived therapies in atrophic AMD and nAMD. A wide variety of cell sources are included in these studies. 
Ongoing studies

Conclusion
The limitations of anti-VEGF therapy in the treatment of nAMD and the lack of effective treatment for nonexudative AMD demonstrate the need for new therapies. Stem cell-based therapies are an intriguing therapeutic option and have been extensively investigated over the last several decades. Induced PSC therapies are of particular interest because of their reduced immunogenicity and their potential for reduced ethical controversy over hESC-based therapies. A decade of preclinical studies improving the safety and efficiency of iPSC-derived RPE transplants paved the way for human trials.
The investigational treatment of a 70-year-old Japanese woman was the first published utilization of iPSCs in humans, and is a major investigational milestone. The major limitation of applying stem cellbased therapies to patients with AMD is the chronic and complex disease process that needs to be overcome. Despite these limitations, RIKEN and Moorefields Eye Hospital are planning on further studies utilizing iPSCs in the treatment nAMD and non-neovascular AMD, and their results will be eagerly awaited.
Expert Opinion
The use of iPSCs was first performed on a Japanese female with end-stage AMD, and this marked a major milestone as the first application of iPSC-based therapy in humans. The preceding decade of advancement in the generation and differentiation of iPSCs, which started in 2006 with the discovery of Yamanaka factors, as well as previous research into RPE transplantation, has allowed for the rapid translation of bench research to clinical trials.
Induced PSC-derived transplants are a promising investigational therapy in AMD research due to the potential for reduced ethical controversy over hESC-based therapies, as well as their reduced immunogenicity. A dampened immune response could improve the survival and function of transplants as well as potentially minimize the need for chronic powerful perioperative systemic immunosuppressive agents. Research into hESCs has demonstrated the potential harms associated with immunosuppression following subretinal transplantation, as reviewed above.
Disadvantages of iPSC-based therapies include their time-consuming and expensive production, particularly for autologous transplants, as well as their relative genomic instability. The use of autologous cells are estimated to require three months to develop and cost approximately $1,000,000 from harvesting to intraocular implantation [127] . The use of allogenic HLA-matched cells allows for a more efficient and economical application, as well as allowing for a more thorough investigation of potential mutations, and consequently likely represents the future of iPSC-based therapies for human AMD research. RIKEN stopped their trial due to genomic instability noted in a batch of iPSC-based RPE tissue. Despite the unclear clinical significance of this finding, they halted further research and revamped their methods prior to continuing their trial.
Induced PSCs have principally been investigated as subretinal transplants to replace or replenish diseased RPE cells. The advantages of this approach is that RPE cells are damaged in AMD and their replacement could theoretically improve photoreceptor function and survival. However, the limitations are numerous. Native RPE cells have a number of functions and it remains to be seen if iPSC-derived RPE [Type here] cells are able to replicate these roles. Arguably, transplanted cells may not need to replicate all functions to be therapeutically successful, but it remains to be seen if they are able to replicate the essential roles necessary for a reduction in disease progression. Additionally, the replacement of RPE cells may not overcome the AMD-related damage of the CC and BM, and AMD pathology might progress despite a successful transplantation. Furthermore, the long-term survival and proper functioning of transplanted cells in an environment of increased oxidative stress, increased immunogenicity and surrounding tissue damage remains to be seen.
Induced PSCs may have a more promising role in utilizing paracrine effects than direct tissue replacement. It will be interesting to learn if iPSC-derived tissue can be genetically modified to produce locally-acting growth factors. We suspect that stem-cell based therapies for AMD, including iPSCs-based therapies, will likely move in the direction of utilizing paracrine effects. This is due to the complexity of AMD pathogenesis and the questionable benefit of replacing a defective layer such as the RPE when the surrounding tissue is damaged and exposed to increased oxidative stress and pathologic immunogenicity. Pathologies that are less chronic and cause less extensive tissue damage may be more amenable to direct tissue replacement. Alternatively, advancements in our understanding of photoreceptor transplant interaction with host tissue, in particular the transfer of proteins and/or RNA from transplanted photoreceptors to host tissue as was discovered recently, may hold promise. Additionally, choroidal cell generation from iPSCs has recently been published [198] , and a combination of tissues may eventually be more effective.
Despite our view that the paracrine effects of transplanted tissue holds the most promise for AMD treatment at this moment, rapid advancements in the field of stem cell biology and research just beyond the horizon could easily change this perspective. Overall, the research into iPSC-based therapy is in its nascency. Significant progress is required prior to broad application and major pathophysiological hurdles may eventually limit its success in AMD.
Article Highlights
• In both neovascular and advanced non-neovascular age-related macular degeneration (AMD), stem cell therapy has the potential to improve on current therapeutic limitations.
• Induced pluripotent stem cells (iPSCs) are promising in that they are derived from adult human cells, ameliorating the need for embryonic stem cells (ESCs) and have the potential for reduced immunogenicity.
• Retinal pigment epithelial (RPE) tissue, derived from iPSCs, has undergone the most extensive research in AMD therapy and holds the most promise for application in humans.
• Previous studies investigating adjuvant RPE transplantation combined with choroidal neovascular membrane resection have provided excellent lessons for the application of iPSCbased therapies.
• The use of iPSCs was first performed on a Japanese female with end-stage AMD, and this marked a major milestone as the first application of an iPSC-based therapy in humans.
• Significantly more research is needed to determine the efficacy and safety of transplantation of stem cells in AMD.
